GW Pharmaceuticals Plc American Depositary Shares
GWPH
GWPH was delisted on the 4th of May, 2021.
254 hedge funds and large institutions have $2.93B invested in GW Pharmaceuticals Plc American Depositary Shares in 2018 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 78 increasing their positions, 46 reducing their positions, and 17 closing their positions.
376% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 17
70% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 46
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more funds holding
Funds holding: 191 → 254 (+63)
21% more capital invested
Capital invested by funds: $2.43B → $2.93B (+$502M)
55% less call options, than puts
Call options by funds: $61.8M | Put options by funds: $138M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$110M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$34.5M |
| 3 |
FAM
Fred Alger Management
New York
|
+$32.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.2M |
| 5 |
Barclays
London,
United Kingdom
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$96.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$60.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$44.1M |
| 4 |
PP
Prudential plc
London, England,
United Kingdom
|
-$34.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.6M |
GWPH Hedge Fund Activity: Q2 2018 in Review
254 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2018, worth a combined $2.93B — up 21% from $2.43B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new GWPH positions and 17 closed out — a net gain of 64 holders — while 78 added to existing stakes and 46 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $110M. The largest seller was Scopia Capital Management, cutting an estimated $96.2M.
- 254 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2018, up from 191 in Q1 2018.
- Funds reported $2.93B of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2018, up 21% quarter-over-quarter.
- 81 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2018 and 17 closed out, a net change of +64 holders.
- The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2018 was Lord, Abbett & Co, an estimated $110M added.
- The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2018 was Scopia Capital Management, an estimated $96.2M sold.
Based on aggregated 13F filings for Q2 2018.